Afroditi Karathanasi
Overview
Explore the profile of Afroditi Karathanasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vassiliou A, Osunronbi T, Enyioma S, Rago G, Karathanasi A, Ghose A, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760402
Purpose: Metastatic spinal cord compression (MSCC) is a severe complication of cancer that can lead to irreversible neurological impairment, necessitating prompt recognition and intervention. This retrospective, single-centre study aimed to...
2.
Revythis A, Shah S, Enyioma S, Ghose A, Patel M, Karathanasi A, et al.
Int J Environ Res Public Health
. 2021 Oct;
18(19).
PMID: 34639712
The COVID-19 pandemic has undoubtedly affected all national healthcare systems at different levels. In countries heavily hit by the pandemic, it was reported that healthcare workers were asked to work...
3.
Shah S, Karathanasi A, Revythis A, Ioannidou E, Boussios S
Diseases
. 2021 Jun;
9(2).
PMID: 34064390
Cancer-associated thrombosis (CAT) is a rising and significant phenomenon, becoming the second leading cause of death in cancer patients. Pathophysiology of CAT differs from thrombosis in the non-cancer population. There...
4.
Shah S, Kutka M, Lees K, Abson C, Hadaki M, Cooke D, et al.
J Pers Med
. 2021 Feb;
11(2).
PMID: 33572084
Introduction: Malignant spinal cord compression (MSCC) is one of the most devastating complications of cancer. This event requires rapid decision-making on the part of several specialists, given the risk of...
5.
Boussios S, Moschetta M, Karihtala P, Samartzis E, Sheriff M, Pappas-Gogos G, et al.
Ann Transl Med
. 2021 Jan;
8(24):1706.
PMID: 33490218
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women, potentially due to ineffectiveness of screening tests for early detection. Patients typically present with advanced disease...
6.
E Ryan J, Ganesh V, Karathanasi A, Moschetta M, Sheriff M, B Schofield J, et al.
J BUON
. 2020 Jun;
25(2):612-617.
PMID: 32521842
Langerhans cell histiocytosis (LCH) is disease process characterized by clonal proliferation of CD1a+ dendritic cells within an inflammatory infiltrate of hematopoietic derived cells. LCH can manifest with a broad spectrum...
7.
Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, et al.
J Pers Med
. 2020 May;
10(2).
PMID: 32455595
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women. Two-thirds of patients present at advanced stage at diagnosis, and the estimated 5 year survival rate...
8.
Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, et al.
Drugs R D
. 2020 Mar;
20(2):55-73.
PMID: 32215876
Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through...
9.
Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, et al.
Invest New Drugs
. 2019 Oct;
38(1):181-193.
PMID: 31650446
Epithelial ovarian cancer (EOC) accounts for nearly 90% of all ovarian malignancies. The standard therapeutic strategy includes cytoreductive surgery and neo (adjuvant) platinum-based chemotherapy. Relapse of advanced high grade serous...
10.
Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E, et al.
Diagnostics (Basel)
. 2019 Aug;
9(3).
PMID: 31374917
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to...